Awaiting development: Guidance and quality standards

Showing 71 to 80 of 332

Guidance and quality standards awaiting development
Title	Type
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]	Technology appraisal guidance
Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when induction chemotherapy is unsuitable [ID6601]	Technology appraisal guidance
Delgocitinib for Chronic Hand Eczema [ID12188]	Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150	Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis [TSID11981]	Technology appraisal guidance
Deuruxolitinib for treating alopecia areata [ID6597]	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]	Technology appraisal guidance
Digital technologies that deliver CBT interventions for insomnia and insomnia symptoms (Disordered sleep)	Health technology evaluation
Diverticular disease	Quality standard